Eye.Talk.Tech. | Episode #14 - Clear.Dark.Repeat. Meet Sensity 3. Faster. Built To Last.

In this episode of Eye.Talk.Tech, Dr. Griffin Christenson welcomes Michael Gatti and Warren Modlin to discuss the technology behind HOYA’s Sensity 3 photochromic lenses, the newest addition to the Sensity Family coming April 2026. They discuss the research behind faster fade-back speeds and improved durability. The conversation highlights the importance of understanding patient lifestyles and delivering personalized lens recommendations. The episode also explores HOYA’s innovation strategy and shares key details about the upcoming product launch. Key Takeaways Photochromic lenses are evolving to meet patient demands. Sensity 3 offers a balance between strength and dynamic range. The resilience index measures lens durability and adaptability. HOYA focuses on delivering value through innovative lens technology. The launch of Sensity 3 is a significant advancement in optics. Future iterations of photochromic lenses are in development. Guest Bios Michael Gatti is an Arizona state licensed, ABO and NCLE certified optician, and the Senior Manager of Professional Engagement at HOYA Vision Care. With over 20 years in the optical industry, Michael is an international speaker who has energized audiences across North America with his dynamic storytelling, practical insight, and motivational content. Known for turning complex topics into clear, actionable takeaways, he inspires eye care professionals to embrace change and drive growth in their practices. Warren Modlin has spent over 30 years at the intersection of vision science, product innovation, and business strategy. He began his career as an optometrist and has held global leadership roles at HOYA, Oakley, and Alcon. He is also the founder of NDV Performance, a neurodynamic vision training platform. Chapters 00:00 Introduction to Sensity 3 Launch 02:50 Trends in Photochromic Lenses 05:56 Technological Innovations in Sensity 3 08:56 Patient Experience and Comfort 11:37 The Science Behind Sensity 3 14:48 Addressing Patient Needs 17:49 HOYA's Vision and Market Position 20:45 Next Steps for Clinicians 23:56 Conclusion and Future Outlook Further Resources 🔗Learn more about http://www.hoyavision.us/ 🌐 connect →   / modsmark   and   / michael-gatti-360001184   ↓Download Sensity 3 Sales Aid → https://drive.google.com/file/d/1nGuY... 🎧Listen on Spotify → https://open.spotify.com/episode/3tYs... 🔔 Subscribe for more Eye.Talk.Tech. →    / @fluorescene   #EyeTalkTech #ODsonTechnology #ODsOnFacebook #HOYA #Sensity3 #LensInnovation #PhotochromicLenses #PatientExperience #LensTechnology #OptometryInnovation #Optometry #FutureOfEyeCare #FluoresceneGroup ___________________________ About the podcast Eye.Talk.Tech. is an eye tech education podcast series that brings subject matter experts and real conversations to the intersection of eye care and technology. Each episode explores innovations and future trends that matter to eyecare professionals worldwide. It is hosted by Dr. Griffin Christenson, OD, MS CS - Interactive Intelligence, It’s the flagship videocast of ODs on Technology - a public platform hosting eye tech content, research, and breakthroughs. Visit us at www.odsontechnology.com Who are we We’re a collective of optometrists, educators, researchers, scientists, public health leaders, tech leaders, and eyecare practitioners working behind the scenes. Most of us weren’t taught the role of technology in our clinical or management training; some went back to school in their late 20s / 30s to upskill, while others are self-taught hustlers. However, we all share one common belief and responsibility: Technology is fundamentally transforming how we practice eye care over the next 10 years, and our profession must catch up to lead this wave. This is our effort to bring tech education to our community - in our own language, on our own terms. ___________________________ Disclaimer This episode is for informational purposes only and not medical advice. Always consult a licensed eye care professional. Guest views are their own and do not reflect those of the host, FluoreSCENE Group, or partners. Mentions of products, tech, or treatments are not endorsements and may include off-label or investigational use. Emerging technologies discussed (e.g., AI, digital tools) may be unapproved and evolving. Use clinical judgment before adopting them. Images are for educational use. For credit or removal requests, please contact [email protected].